netFormulary
 Report : Medicines with links to NICE 05/08/2021 18:04:24

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 125mg 10.01.03 Restricted Use NICE TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 125mg 10.01.03 Restricted Use NICE TA280 - Abatacept for Rheumatoid Arthritis after Failure of Conventional Disease-Modifying Anti-rheumatic drugs
Abatacept 250mg 10.01.03 Restricted Use NICE TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 250mg 10.01.03 Restricted Use NICE TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abemaciclib 50mg, 100mg, 150mg 08.01.05 Restricted Use NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abiraterone Actetate 500mg 08.03.04.02 Restricted Use NICE TA 259: Abiraterone for castration resistant prostate cancer
Abiraterone Actetate 500mg 08.03.04.02 Restricted Use NICE TA387: Abiraterone for treating metasatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 40mg 13.05.03 Restricted Use NICE TA 455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 40mg 13.05.03 Restricted Use NICE TA 146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 40mg 13.05.03 Restricted Use NICE TA 199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 40mg 13.05.03 Restricted Use NICE TA 392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 40mg 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 40mg 01.05.03 Restricted Use NICE TA 163: Infliximab for acute exacerbations of ulcerative colitis
Adalimumab 40mg 01.05.03 Restricted Use NICE TA329 Infliximab,adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 40mg 10.01.03 Restricted Use NICE TA 460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 40mg 10.01.03 Restricted Use NICE TA 143 Adalimumab, etanercept and infliximab for ankylosing spondylitis
Adalimumab 40mg 10.01.03 Restricted Use NICE TA 195 Treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 40mg 10.01.03 Restricted Use NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 40mg 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adrenaline / Epinephrine 150micrograms 03.04.03 Formulary NICE CG 134: Anaphylaxis: assessment and referral after emergency treatment
Adrenaline / Epinephrine 300micrograms 03.04.03 Formulary NICE CG 134: Anaphylaxis: assessment and referral after emergency treatment
Adrenaline / Epinephrine 500micrograms 03.04.03 Formulary NICE CG 134: Anaphylaxis: assessment and referral after emergency treatment
Afatinib 20mg, 30mg, 40mg, 50mg 08.01.05 Restricted Use NICE TA310: Afatinib for epidermal growth factor receptor mutation-positive locally advanced or metatstatic non-small-cell lung cancer
Aflibercept 4mg/0.1mL 11.08.02 Restricted Use NICE TA 346: Aflibercept for treating diabetic macular oedema
Aflibercept 4mg/0.1mL 11.08.02 Restricted Use NICE TA 486: Aflibercept for treating choroidal neovascularisation
Aflibercept 4mg/0.1mL 11.08.02 Restricted Use NICE TA294: Macular Degeneration (wet age-related) - aflibercept
Aflibercept 4mg/0.1mL 11.08.02 Restricted Use NICE TA305: Macular Oedema (central retinal vein occlusion) - aflibercept solution for injection
Aflibercept 4mg/0.1mL 11.08.02 Restricted Use NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alemtuzumab 12mg/1.2mL 08.02.03 Restricted Use NICE TA312: Alemtuzumab for relapsing-remitting multiple sclerosis
Alirocumab 75mg/ml, 150mg/ml 02.12 Restricted Use NICE TA 393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 10mg, 30mg 13.05.01 Restricted Use NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 50mg 02.10.02 Restricted Use NICE TA264: Alteplase for treating acute ischaemic stroke
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TAG156: Anti-D in pregnant women
Apixaban 2.5mg, 5mg 02.08.02 Restricted Use NICE TA 275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 2.5mg, 5mg 02.08.02 Restricted Use NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast titration pack, 30mg 13.05.03 Restricted Use NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast titration pack, 30mg 10.01.03 Restricted Use NICE TA 433: Apremilast for treating active psoriatic arthritis
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 1200mg/20mg 08.01.05 Restricted Use NICE TA 639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Autologous anti-CD19-transduced CD3+ cells 08.01.05 Formulary NICE TA 677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma
Avatrombopag Doptelet® 20mg 09.01.04 Formulary NICE TA 626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab 200mg/10mL 08.01.05 Restricted Use NICE TA 517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 200mg/10mL 08.01.05 Restricted Use NICE TA 645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Axicabtagene ciocleucel 08.01.05 Restricted Use NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 1mg, 3mg, 5mg, 7mg 08.01.05 Restricted Use NICE TA 333: Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 100mg 08.01.03 Restricted Use NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 100mg 08.01.03 Non Formulary NICE TA 399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Baricitinib 2mg, 4mg 13.05.03 Restricted Use NICE TA 681: Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib 2mg, 4mg 10.01.03 Restricted Use NICE TA 466: Baricitinib for moderate to severe rheumatoid arthritis
Belimumab 120mg, 400mg 10.01.03 Restricted Use NICE TA 397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 25mg, 100mg 08.01.01 Restricted Use NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Benralizumab 30mg/mL 03.04.02 Restricted Use NICE TA 565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Non Formulary NICE TA 560: Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
Bevacizumab 100mg/4mL, 400mg/16mL 08.01.05 Restricted Use NICE TA263: Bevacizumab in combination wtih capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 100mg/4mL, 400mg/16mL 08.01.05 Restricted Use NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Binimetinib 50mg, 75mg 08.01.05 Restricted Use NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Bivalirudin 250mg 02.08.01 Restricted Use NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 38.5 micrograms 08.01.05 Restricted Use NICE TA 450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 200mg 05.03.03.02 Restricted Use NICE TA 253: Boceprevir for the treatment of Genotype 1 Chronic Hepatitis C
Bortezomib 3.5mg 08.01.05 Restricted Use NICE TA 311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 3.5mg 08.01.05 Restricted Use NICE TA 228 Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 3.5mg 08.01.05 Restricted Use NICE TA 370: Bortezomib for previously untreated mantle cell lymphoma
Bosutinib 100mg, 500mg 08.01.05 Restricted Use NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 50 Unit, 100unit 04.09.03 Restricted Use NICE TA 260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab 50mg 08.01.05 Restricted Use NICE TA 577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma in adults
Brentuximab 50mg 08.01.05 Restricted Use NICE TA 446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab 50mg 08.01.05 Restricted Use NICE TA 641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brentuximab 50mg 08.01.05 Restricted Use NICE TA 478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brigatinib 30mg, 60mg, 90mg 08.01.05 Restricted Use NICE TA 571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brigatinib 30mg, 60mg, 90mg 08.01.05 Restricted Use NICE TA 670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
Brodalumab 210mg 13.05.03 Restricted Use NICE TA 511: Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab 120mg/mL 11.08.02 Restricted Use NICE TA 672: Brolucizumab for treating wet age-related macular degeneration
Buprenorphine 400micrograms, 4mg, 8mg 04.10.03 Restricted Use NICE TA 114: Methadone and buprenorphine for the management of opioid dependence
Cabazitaxel 60mg in 1.5ml 08.01.05 Restricted Use NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 20mg, 40mg, 60mg 08.01.05 Restricted Use NICE TA 463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 20mg, 40mg, 60mg 08.01.05 Restricted Use NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 20mg, 40mg, 60mg 08.01.05 Restricted Use NICE TA 516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 100mg, 300mg 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin, empagliflozin as monotherapies for treating Type 2 diabetes
Canagliflozin 100mg, 300mg 06.01.02.03 Restricted Use NICE TA315: Canagliflozin in combination therapy for treating Type 2 diabetes
Capecitabine 150mg, 500mg 08.01.03 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 150mg, 500mg 08.01.03 Restricted Use NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 150mg, 500mg 08.01.03 Restricted Use NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Caplacizumab 10mg 08.02.03 Restricted Use NICE TA 667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carfilzomib 10mg, 30mg, 60mg 08.01.05 Restricted Use NICE TA 657: Carfilzomib for previously treated multiple myeloma
Carmustine 100mg 08.01.01 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine 7.7mg 08.01.01 Restricted Use NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Cemiplimab 350mg 08.01.05 Formulary NICE TA 592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 150mg 08.01.05 Formulary NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 150mg 08.01.05 Formulary NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 200mg 13.05.03 Restricted Use NICE TA 574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab pegol 200mg 13.05.03 Restricted Use NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA 415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab 100mg/20mL, 500mg/100mL 08.01.05 Restricted Use NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Cetuximab 100mg/20mL, 500mg/100mL 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 1mg/ml 11.04.02 Restricted Use NICE TA369 - Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 30mg, 60mg, 90mg 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Colecalciferol/Calcium Carbonate 10micrograms (400units)/1.5g 09.06.04 Restricted Use NICE Quality Standard 85: Medicines management in care homes
Colistimethate Sodium 1,662,500IU 05.01.07 Restricted Use NICE TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Continuous Subcutaneous Insulin Infusion 06.01.01 Restricted Use NICE TA 151: Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (Type 1)
Crizotinib 200mg,250mg 08.01.05 Restricted Use NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 200mg,250mg 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran etexilate 110mg, 150mg 02.08.02 Restricted Use NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran etexilate 110mg, 150mg 02.08.02 Restricted Use NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib 08.01.05 Non Formulary NICE TA 564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
Dabrafenib 50mg, 75mg 08.01.05 Restricted Use NICE TA 321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Dabrafenib 50mg, 75mg 08.01.05 Restricted Use NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Daclatasvir 30mg, 60mg 05.03.03.02 Restricted Use NICE TA364 - Daclatasvir for treating chronic hepatitis C
Daclizumab 150mg 08.02.02 Non Formulary NICE TA 441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 390: Canagliflozin, dapagliflozin, empagliflozin as monotherapies for treating Type 2 diabetes
Dapagliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 100mg/5mL, 400mg/20mL 08.01.05 Restricted Use NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab 100mg/5mL, 400mg/20mL 08.01.05 Restricted Use NICE TA 510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darbepoetin Alfa 10, 15, 20, 30, 40, 50, 60, 80, 100, 150micrograms 09.01.03 Restricted Use NICE TA 142: Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia
Darolutamide 300mg 08.03.04.02 Restricted Use NICE TA 660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Darvadstrocel 01.07.04 Non Formulary NICE TA 556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasatinib 20mg, 50mg, 80mg, 100mg, 140mg 08.01.05 Restricted Use NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 20mg, 50mg, 80mg, 100mg, 140mg 08.01.05 Restricted Use NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA 548: Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Degarelix 80mg, 120mg 08.03.04.02 Restricted Use NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 120mg/1.7mL 06.06.02 Non Formulary NICE TA 549: Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Denosumab 120mg/1.7mL 06.06.02 Restricted Use NICE TA265 Bone Metastases from Solid Tumours - Denosumab
Dexamethasone 700micrograms 11.04.01 Restricted Use NICE TA 229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone 700micrograms 11.04.01 Restricted Use NICE TA 349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl Fumarate 120mg, 240mg 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for relapsing-remitting multiple sclerosis
Dimethyl fumarate 30mg, 120mg 13.05.03 Restricted Use NICE TA 475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 20mg/0.5ml/80mg/2ml 08.01.05 Restricted Use NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 20mg/0.5ml/80mg/2ml 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin Hydrochloride (encapsulated in liposomes) 20mg, 50mg 08.01.02 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxorubicin Hydrochloride (encapsulated in liposomes) 20mg, 50mg 08.01.02 Restricted Use NICE TA 465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Dronedarone 400mg 02.03.02 Restricted Use NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab 300mg 13.05.03 Restricted Use NICE TA 534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 120mg/2.4mL, 500mg/10mL 08.01.05 Restricted Use NICE TA 578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 300mg 09.01.03 Restricted Use NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban 15mg, 30mg, 60mg 02.08.02 Restricted Use NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 15mg, 30mg, 60mg 02.08.02 Restricted Use NICE TA 354:Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir/Grazoprevir 50mg/100mg 05.03.03.02 Restricted Use NICE TA 413: Elbasvir–grazoprevir for treating chronic hepatitis C
Elosulfase alfa 5mg/5ml 16.01 Restricted Use NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa
Elosulfase alfa 5mg/5ml 16.01 Restricted Use Managed access agreement - Elosulfase alfa for treating mucopolysaccharidosis type IVa
Eltrombopag 25mg, 50mg 09.01.04 Restricted Use NICE TA 293: Eltrombopag for treating chronic immune idiopathic thrombocytopenia purpura (review of TA 205)
Empagliflozin 10mg, 25mg 06.01.02.03 Restricted Use NICE TA336: Empagliflozin in combination therapy for treating Type 2 diabetes
Empagliflozin 10mg, 25mg 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin, empagliflozin as monotherapies for treating Type 2 diabetes
Encorafenib 50mg, 75mg 08.01.05 Restricted Use NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Encorafenib 50mg, 75mg 08.01.05 Restricted Use NICE TA 668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Entecavir 500micrograms, 1mg 05.03.03 Restricted Use Hepatitis B (chronic): diagnosis and management
Entecavir 500micrograms, 1mg 05.03.03 Restricted Use NICE TA153: Hepatitis B - entecavir
Entrectinib 100mg, 200mg 08.01.05 Formulary NICE TA 643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Entrectinib 100mg, 200mg 08.01.05 Formulary NICE TA 644: Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide 40mg 08.01.05 Non Formulary NICE TA 580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
Enzalutamide 40mg 08.03.04.02 Restricted Use NICE TA 377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 40mg 08.03.04.02 Restricted Use NICE TA 316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Eplerenone 25mg, 50mg 02.02.03 Formulary NICE CG108: Chronic heart failure
Eplerenone 25mg, 50mg 02.02.03 Formulary NICE CG 172: Myocardial Infarction - Secondary Prevention
Epoetin ALFA 1000, 2000, 3000, 4000, 5000, 6000units 09.01.03 Restricted Use NICE TA142: Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia
Epoetin BETA 1000, 2000, 3000, 5000, 6000units 09.01.03 Restricted Use NICE TA 142: Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia
Erenumab 70mg/1mL, 140mg/1mL 04.07.04.02 Formulary NICE TA 682: Erenumab for preventing migraine
Eribulin 08.01.05 Non Formulary NICE TA 515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Eribulin 0.88mg, 1.32mg 08.01.05 Restricted Use NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 25mg, 100mg, 150mg 08.01.05 Restricted Use NICE TA 258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 25mg, 100mg, 150mg 08.01.05 Restricted Use NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 5mg, 10mg 06.01.02.03 Restricted Use NICE TA 583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 25mg, 50mg 10.01.03 Restricted Use NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Etanercept 25mg, 50mg 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 25mg, 50mg 10.01.03 Restricted Use NICE TA143: Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis
Etanercept 25mg, 50mg 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 25mg, 50mg 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 25mg, 50mg 13.05.03 Restricted Use NICE TA 199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 25mg, 50mg 13.05.03 Restricted Use NICE TA 455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etelcalcetide 2.5mg/0.5mL, 5mg/1mL, 10mg/2mL 09.05.01.02 Restricted Use NICE TA 448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 2.5mg, 5mg, 10mg 08.01.05 Restricted Use NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 2.5mg, 5mg, 10mg 08.01.05 Restricted Use NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 2.5mg, 5mg, 10mg 08.01.05 Restricted Use NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 140mg/ml 02.12 Formulary NICE TA 394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 2mg 06.01.02.03 Restricted Use NICE NG28: Type 2 diabetes in adults: management
Ezetimibe 10mg 02.12 Restricted Use NICE CG 181: Cardiovascular disease: risk assessment and reduction, including lipid modification
Ezetimibe 10mg 02.12 Restricted Use NICE CG 71: Familial hypercholesterolaemia: identification and management
Ezetimibe 10mg 02.12 Restricted Use NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 80mg, 120mg 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Filgotinib 100mg, 200mg 10.01.03 Restricted Use NICE TA 676: Filgotinib for treating moderate to severe rheumatoid arthritis
Finasteride 5mg 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 500micrograms 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 10mg 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 10mg 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 50mg 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 50mg 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fluocinolone Acetonide 190 micrograms 11.04.01 Restricted Use NICE TA 301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fremanezumab (Ajovy®) 225mg/1.5mL 04.07.04.02 Formulary NICE TA 631: Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Non Formulary NICE TA 503: Fulvestrant for untreated locally advances or metastatic oestrogen-receptor positive breast cancer
Galcanezumab 120mg/1mL 04.07.04.02 Formulary NICE TA 659: Galcanezumab for preventing migraine
Gefitinib 250mg 08.01.05 Restricted Use NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gefitinib 250mg 08.01.05 Non Formulary NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 200mg, 1g 08.01.03 Restricted Use NICE TA116: Breast cancer - gemcitabine
Gemcitabine 200mg, 1g 08.01.03 Restricted Use NICE TA25: Pancreatic cancer - gemcitabine
Gemtuzumab ozogamicin 5mg 08.01.05 Restricted Use NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 40mg 08.01.05 Formulary NICE TA 642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glatiramer Acetate 20mg/1mL, 40mg/1mL 08.02.04 Restricted Use NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir/ pibrentasvir 100mg/40mg 05.03.03.02 Restricted Use NICE TA 499: Glecaprevir-pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 50mg 10.01.03 Restricted Use NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 50mg 10.01.03 Restricted Use NICE TA220: Psoriatic arthritis - golimumab
Golimumab 50mg 10.01.03 Restricted Use NICE TA225: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 50mg 10.01.03 Restricted Use NICE TA 497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 50mg 01.05.03 Restricted Use NICE TA329 Infliximab,adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Guselkumab 100mg 13.05.03 Restricted Use NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA 429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 100mg, 125mg 08.01.05 Restricted Use NICE TA359 - Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for first-line treatment of chronic myeloid leukaemia
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA326: Imatinib for Adjuvant Treatment Gastro-intestinal Stromal Tumours (GIST) -review NICE TA 196
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 100mg, 400mg 08.01.05 Restricted Use NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 100mg 13.05.03 Restricted Use NICE TA 134: Infliximab for psoriasis
Infliximab 100mg 13.05.03 Restricted Use NICE TA 199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Infliximab 100mg 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 100mg 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 100mg 10.01.03 Restricted Use NICE TA 375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 100mg 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 100mg 01.05.03 Restricted Use NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 100mg 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 100mg 01.05.03 Restricted Use NICE TA329 Infliximab,adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Interferon Beta-1a 6 million units, 22 micrograms/0.5mL 08.02.04 Restricted Use NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1a 6million units, 30micrograms/0.5mL 08.02.04 Restricted Use NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1b 9.6million units (300micrograms) 08.02.04 Restricted Use NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 50mg/10mL, 200mg/40mL 08.01.05 Restricted Use NICE TA 319:Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 50mg/10mL, 200mg/40mL 08.01.05 Restricted Use NICE TA 268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 50mg/10mL, 200mg/40mL 08.01.05 Restricted Use NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Irinotecan Hydrochloride 40mg/2mL, 100mg/5mL 08.01.05 Restricted Use NICE CG131: Colorectal cancer: diagnosis and management
Isatuximab 100mg/5mL 08.01.05 Formulary NICE TA 658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Isatuximab 100mg/5mL 08.01.05 Formulary NICE TA 658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 5mg, 7.5mg 02.06.03 Restricted Use NICE TA 267: Ivabradine for treating chronic heart failure
Ixazomib 2.3mg, 3mg, 4mg 08.01.05 Restricted Use NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 80mg 13.05.03 Restricted Use NICE TA 442: Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 100mg 05.03.01 Restricted Use NICE TA 96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Lanadelumab 300mg/2mL 03.04.03 Restricted Use NICE TA 606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenvatinib 4mg, 10mg 08.01.05 Restricted Use NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 200mg 10.01.04 Non Formulary NICE TA 506: Lesinurad for treating chronic hyperuricaemia in people with gout
Liposomal cytarabine-daunorubicin 44mg/100mg 08.01.05 Restricted Use NICE TA 552: Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia
Liraglutide 6mg/1mL 04.05.01 Restricted Use NICE TA 664: Liraglutide for managing overweight and obesity
Liraglutide 6mg/mL 06.01.02.03 Formulary NICE NG28: Type 2 Diabetes in adults: management
Lumacaftor/ivacaftor 200mg/125mg 03.07 Non Formulary NICE TA 398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Mannitol 40mg 03.07 Restricted Use NICE TA266 Mannitol dry powder for inhalation for treating cystic fibrosis
Melatonin 2mg 04.01.01 Formulary NICE NG 62: Cerebral palsy in under 25s: assessment and management
Melatonin 2mg 04.01.01 Formulary NICE NG 11: Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges
Melatonin 2mg 04.01.01 Formulary NICE CG 170: Autism spectrum disorder in under 19s: support and management
Mepolizumab 100mg 03.04.02 Restricted Use NICE TA 671: Mepolizumab for treating severe eosinophilic asthma
Methylprednisolone 100mg 06.03.02 Restricted Use NICE CG186: Multiple Sclerosis in adults : management
Midostaurin 25mg 08.01.05 Restricted Use NICE TA 523: Midostaurin for untreated acute myeloid leukaemia
Mirabegron 25mg, 50mg 07.04.02 Formulary NICE TA290 Overactive bladder - Mirabegron
Naftidrofuryl Oxalate 100mg 02.06.04 Restricted Use NICE TA 223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Naldemedine 200microgram 01.06 Formulary NICE TA651: Naldemedine for treating opioid-induced constipation
Nalmefene 18mg 04.10.01 Restricted Use NICE TA 325 Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence
Naloxegol 12.5mg, 25mg 01.06 Restricted Use NICE TA345: Naloxegol for treating opioid-induced constipation
Naltrexone Hydrochloride 50mg 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Natalizumab 300mg/15mL 08.02.04 Restricted Use NICE TA127: Multiple sclerosis - natalizumab
Neratinib 40mg tablet 08.01.05 Restricted Use NICE Technology Appraisal (TA) 612
Nilotinib 150mg, 200mg 08.01.05 Restricted Use NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 150mg, 200mg 08.01.05 Restricted Use NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 150mg, 200mg 08.01.05 Restricted Use NICE TA 251:Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of TA 70)
Nintedanib 100mg, 150mg 08.01.05 Restricted Use NICE TA347: Nitedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Nintedanib 100mg, 150mg 03.11 Restricted Use NICE TA379: Nintedanib for treating indiopatic pulmonary fibrosis
Niraparib 100mg 08.01.05 Restricted Use NICE TA 673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Niraparib 100mg 08.01.05 Restricted Use NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 40mg/4mL, 100mg/10mL 08.01.05 Restricted Use NICE TA 684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nusinersen 12mg / 5mL 10.02 Restricted Use NICE TA 588: Nusinersen for treating spinal muscular atrophy
Obinutuzumab 1000mg/40mL 08.02.03 Restricted Use NICE TA 629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Obinutuzumab 1000mg/40mL 08.02.03 Restricted Use NICE TA 472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 1000mg/40mL 08.02.03 Restricted Use NICE TA 513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 1000mg/40mL 08.02.03 Restricted Use NICE TA 343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ocrelizumab 300mg 08.01.01 Restricted Use NICE TA 533: Ocrelizumab for treating relapsing-remitting multiple sclerosis
Ocrelizumab 300mg 08.01.01 Restricted Use NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 0.5mg in 0.2mL 11.08.02 Restricted Use NICE TA 297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 100mg, 1000mg 08.02.03 Restricted Use NICE TA 344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib 100mg, 150mg 08.01.05 Formulary NICE TA 620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 100mg, 150mg 08.01.05 Formulary NICE TA 598. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaparib 50mg - DELETE 08.01.05 Restricted Use NICE TA 381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab 190mg/19mL, 500mg/50mL 08.01.05 Restricted Use NICE TA 465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 150mg 03.04.02 Restricted Use NICE TA 278 Omalizumab for treating severe persistent allergic asthma
Omalizumab 150mg 03.04.02 Restricted Use NICE TA339: Omalizumab for previously trated chronic spontaneous urticaria
Osimertinib 40mg, 80mg 08.01.05 Restricted Use NICE TA 654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Osimertinib 40mg, 80mg 08.01.05 Restricted Use NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Oxaliplatin 50mg, 100mg 08.01.05 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxaliplatin 50mg, 100mg 08.01.05 Restricted Use NICE CG131: Colorectal cancer management and diagnosis
Oxytocin 5units/mL, 10units/mL 07.01.01 Formulary NICE CG 55: Intrapartum care: Care of healthy women and their babies during childbirth
Paclitaxel 30mg/5mL, 100mg/16.7mL, 300mg/50mL 08.01.05 Restricted Use NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel albumin 100mg, 250mg 08.01.05 Restricted Use NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 100mg, 125mg, 75mg 08.03.04.01 Restricted Use NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 100mg/5mL, 400mg/20mL 08.01.05 Restricted Use NICE TA 242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy
Panitumumab 100mg/5mL, 400mg/20mL 08.01.05 Restricted Use NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 10mg, 15mg, 20mg 08.01.05 Restricted Use NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer 8.4g, 16.8g 09.02.01.01 Formulary NICE TA 623: Patiromer for treating hyperkalaemia
Pazopanib 200mg, 400mg 08.01.05 Restricted Use NICE TA215: Pazopanib for the first-line treatment of adcanced renal cell carcinoma
Pegaspargase 750units/ml 08.01.05 Restricted Use NICE TA 408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa-2a 135micrograms, 180micrograms 08.02.04 Restricted Use NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa-2a 135micrograms, 180micrograms 08.02.04 Restricted Use NICE TA 75: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2a 135micrograms, 180micrograms 08.02.04 Restricted Use NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 50micrograms, 80micrograms, 100micrograms, 120micrograms, 150micrograms 08.02.04 Restricted Use NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa-2b 50micrograms, 80micrograms, 100micrograms, 120micrograms, 150micrograms 08.02.04 Restricted Use NICE TA 75: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 50micrograms, 80micrograms, 100micrograms, 120micrograms, 150micrograms 08.02.04 Restricted Use NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA 531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 100mg/4mL 08.02.03 Restricted Use NICE TA 522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 50mg 08.02.03 Restricted Use NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pemetrexed 500mg 08.01.03 Restricted Use NICE TA190:Pemetrexed for maintenance treatment of non-small-cell lung cancer
Pemetrexed 500mg 08.01.03 Restricted Use NICE TA181:Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 500mg 08.01.03 Restricted Use NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pemetrexed 500mg 08.01.03 Restricted Use NICE TA 402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pertuzumab 420mg/14ml 08.01.05 Restricted Use NICE TA 569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 420mg/14ml 08.01.05 Restricted Use NICE TA 424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 420mg/14ml 08.01.05 Restricted Use NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 1% 13.05.03 Restricted Use NICE TA 82: Tacrolimus anad pimecrolimus for atopic eczema
Pirfenidone 267mg 03.11 Restricted Use NICE TA 504: Pirfenidone for treating Idiopathic Pulmonary Fibrosis
Pixantrone 29mg 08.01.02 Restricted Use NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkins B-cell lymphoma
Polatuzumab vedotin 140mg 08.01.05 Formulary NICE TA 649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Pomalidomide 1mg, 2mg, 3mg, 4mg 08.02.04 Restricted Use NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Restricted Use NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 5mg, 10mg 02.09 Restricted Use NICE TA182: Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
Prucalopride 1mg, 2mg 01.06.07 Restricted Use NICE TA211: Prucalopride for the treatment of chronic constipation in women
Radium-223 dichloride 1000 kBq/ml 08.03.04.02 Restricted Use NICE TA412 - Radium-223 dichloride for hormone relapsed prostate cancer with bone metasteses
Raloxifene 60mg 06.04.01.01 Formulary NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raltitrexed 08.01.03 Restricted Use NICE CG131: Colorectal cancer: diagnosis and management
Ranibizumab 1.65mg in 0.165ml 11.08.02 Restricted Use NICE TA155: Macular degeneration (age-related) ranibizumab
Ranibizumab 1.65mg in 0.165ml 11.08.02 Restricted Use NICE TA274: Macular oedema (diabetic) ranibizumab
Ranibizumab 1.65mg in 0.165ml 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion) ranibizumab
Ranibizumab 1.65mg in 0.165ml 11.08.02 Restricted Use NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 2.3mg/0.23mL 11.08.02 Restricted Use NICE TA155: Macular degeneration (age-related) ranibizumab
Ranibizumab 2.3mg/0.23mL 11.08.02 Restricted Use NICE TA274: Macular oedema (diabetic) ranibizumab
Ranibizumab 2.3mg/0.23mL 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion) ranibizumab
Ranibizumab 2.3mg/0.23mL 11.08.02 Restricted Use NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Regorafenib 08.01.05 Restricted Use NICE TA 514: Regorafenib for previously treated advanced hepatocellular
Regorafenib 40mg 08.01.05 Restricted Use NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 40mg 08.01.05 Restricted Use NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab 25mg/ 2.5mL, 100mg/ 10mL 03.04.02 Restricted Use NICE TA 479: Reslizumab for treating severe eosinophilic asthma
Retigabine 50mg, 100mg, 200mg, 300mg, 400mg 04.08.01 Non Formulary NICE TA 232: Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
Ribavirin 200mg 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 200mg 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 200mg 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 6g 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 6g 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 6g 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 200mg 08.03.04.01 Restricted Use NICE TA 687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Ribociclib 200mg 08.03.04.01 Restricted Use NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 550mg 05.01.07 Restricted Use NICE TA 337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 50mg 04.09.03 Restricted Use NICE TA 20: Use of riluzole (Rilutek) for the treatment of motor neurone disease
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 174: Rituximab for first line treatment of chronic lymphocytic leukaemia
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (review of TA 37)
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 226: Rituximab for the treatment of follicular non-Hodgkins lymphoma (maintenance treatment following response to first-line chemotherapy)
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 243: Follicular lymphoma
Rituximab 100mg/10mL, 500mg/50mL 08.02.03 Restricted Use NICE TA 308: Rituximab in combination with glucocorticoids for treating ANCA-associated Vasculitis
Rituximab 100mg/10mL, 500mg/50mL 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 1400mg 08.02.03 Restricted Use NICE TA 226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin;s lymphoma
Rivaroxaban 10mg, 15mg, 20mg 02.08.02 Restricted Use NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF
Rivaroxaban 10mg, 15mg, 20mg 02.08.02 Restricted Use NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 10mg, 15mg, 20mg 02.08.02 Restricted Use NICE TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban
Rivaroxaban 15mg, 20mg 02.08.02 Restricted Use NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF
Rivaroxaban 2.5mg 02.08.02 Restricted Use NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban 2.5mg 02.08.02 Restricted Use NICE TA 335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Roflumilast 03.03.03 Formulary NICE TA 461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 250micrograms 09.01.04 Restricted Use NICE TA 221: Romiplostim for the treatment of chronic immune idiopathic thrombocytopenia purpura
Ruxolitinib 5mg, 10mg, 15mg, 20mg 08.01.05 Restricted Use NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril/Valsartan 24mg/26mg 49mg/51mg 97mg/103mg 02.05.05.02 Restricted Use NICE TA388 - Sacubitril Valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Secukinumab 150mg 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 150mg 10.01.03 Restricted Use NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 150mg 10.01.03 Restricted Use NICE TA 407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Simeprevir 150mg 05.03.03.02 Restricted Use NICE TA 331: Simeprevir in combination with peginterferon and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Siponimod 250micrograms, 2mg 08.02.04 Formulary NICE TA 656: Siponimod for treating secondary progressive multiple sclerosis
Sodium Tetradecyl Sulfate 3% 02.13 Restricted Use NICE CG 168: Varicose veins in the legs
Sodium zirconium cyclosilicate 5g, 10g 09.02.01.01 Formulary NICE TA 599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 400mg 05.03.03.02 Restricted Use NICE TA 330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/ Velpatasvir 400mg/100mg 05.03.03.02 Restricted Use NICE TA 430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir/ velpatasvir/ voxilprevir 400mg/100mg/100mg 05.03.03.02 Restricted Use NICE TA 507: Sofosbuvir-velpatasvir-votilaprevir for treating chronic hepatitis C
Sofosbuvir/Ledipasvir 400mg/90mg 05.03.03.02 Restricted Use NICE TA363 - Ledipasvir-sofosbuvir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 200mg 08.01.05 Restricted Use NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sotagliflozin 200mg 06.01.02.03 Formulary NICE TA 622: Sotagliflozin with insulin for treating type 1 diabetes
Strimvelis 09.08.01 Restricted Use NICE HST7: Strimvelis for treating adenosine deaminase deficiency-severe combined immunodeficiency
Sunitinib 12.5mg, 25mg, 50mg 08.01.05 Restricted Use NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib 12.5mg, 25mg, 50mg 08.01.05 Restricted Use NICE TA178: Renal cell carcinoma
Sunitinib 12.5mg, 25mg, 50mg 08.01.05 Restricted Use NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 12.5mg, 25mg, 50mg 08.01.05 Restricted Use NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 0.03%, 0.1% 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Tacrolimus 500micrograms, 1mg, 5mg 13.05.03 Restricted Use NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Talimogene laherparepvec 08.02.04 Restricted Use NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 375mg 05.03.03.02 Restricted Use NICE TA 252: Telaprevir for the treatment of Genotype 1 Chronis Hepatitis C
Temozolomide 5mg, 20mg, 100mg, 140mg, 180mg, 250mg 08.01.05 Restricted Use NICE TA 23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 5mg, 20mg, 100mg, 140mg, 180mg, 250mg 08.01.05 Restricted Use NICE TA 121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disoproxil 245mg 05.03.01 Restricted Use NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Tenofovir Disoproxil 245mg 05.03.01 Restricted Use NICE CG165: Hepatitis B (chronic): diagnosis and management
Teriflunomide 14mg 08.02.04 Restricted Use NICE TA 303 Teriflunomide for Relapsing-remitting Multiple Sclerosis
Teriparatide 20 micrograms / 80 microlitres solution for injection 2.4mL cartridge with pen 06.06.01 Formulary NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Teriparatide 20 micrograms / 80 microlitres solution for injection 2.4mL pen 06.06.01 Formulary NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 50mg 08.02.04 Restricted Use NICE TA 228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Tildrakizumab 100mg 13.05.03 Restricted Use NICE TA 575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tirofiban 250micrograms/1mL 02.09 Restricted Use NICE TA 47: The use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Tisagenlecleucel 08.01.05 Restricted Use NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.01.05 Restricted Use NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 890micrograms, 1340micrograms 08.01.05 Restricted Use NICE TA 512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin 28mg/capsule 05.01.04 Restricted Use NICE TA 276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tofacitinib 5mg 10.01.03 Restricted Use NICE TA 480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 5mg 10.01.03 Restricted Use NICE TA 543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 5mg, 10mg 01.05.03 Restricted Use NICE TA 547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 15mg, 30mg, 45mg, 60mg, 90mg 06.05.02 Restricted Use NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 250micrograms, 1mg 08.01.05 Restricted Use NICE TA184: Topotecan (oral) for treatment of relapsed small-cell lung cancer
Topotecan 250micrograms, 1mg 08.01.05 Restricted Use NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 250micrograms, 1mg 08.01.05 Restricted Use NICE TA91: Topotecan for ovarian cancer
Topotecan 4mg 08.01.05 Non Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 4mg 08.01.05 Restricted Use NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 4mg 08.01.05 Restricted Use NICE TA183: Cervical cancer (recurrent) - topotecan
Trabectedin 08.01.05 Restricted Use NICE TA 185: Trabectedin for the treatment of advanced soft tissue sarcoma
Trabectedin 08.01.05 Non Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 0.5mg, 2mg 08.01.05 Formulary NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 0.5mg, 2mg 08.01.05 Formulary NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 150mg 08.01.05 Restricted Use NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab 150mg 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 150mg 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 600mg/5mL 08.01.05 Restricted Use NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab 600mg/5mL 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab emtansine 100mg, 160mg 08.01.05 Restricted Use NICE TA 458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine 100mg, 160mg 08.01.05 Restricted Use NICE TA 632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Treosulfan 1g, 5g 08.01.01 Formulary NICE TA 640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Trifluridine-tipiracil 15mg/6.14mg, 20mg/8.19mg 08.01 Restricted Use NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Upadacitinib 15mg 10.01.03 Restricted Use NICE TA 665: Upadacitinib for treating severe rheumatoid arthritis
Ustekinumab 45mg/0.5mL 13.05.03 Restricted Use NICE TA 455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 45mg/0.5mL 13.05.03 Restricted Use NICE TA 180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 45mg/0.5mL 13.05.03 Restricted Use NICE TA 340: Ustekinumab for treating active psoriatic arthritis (rapid review TA 313)
Ustekinumab 45mg/0.5mL, 90mg/1mL, 130mg/26mL 01.05.03 Restricted Use NICE TA 456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 45mg/0.5mL, 90mg/1mL, 130mg/26mL 01.05.03 Restricted Use NICE TA 633: Ustekinumab for treating moderately to severely active ulcerative colitis
Vandetanib 08.01.05 Non Formulary NICE TA 550: Vandetanib for treating medullary thyroid cancer
Varenicline 500micrograms, 1mg 04.10.02 Restricted Use NICE TA123: Varenicline
Vedolizumab 300mg 01.05.03 Restricted Use NICE TA 342: Vedolizumab for treating moderately to severely active Ulcerative Colitis
Vedolizumab 300mg 01.05.03 Restricted Use NICE TA 352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib 240mg 08.01.05 Restricted Use NICE TA 269; Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Venetoclax 10mg, 50mg, 100mg 08.01.05 Restricted Use NICE TA 487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 10mg, 50mg, 100mg 08.01.05 Restricted Use NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 10mg, 50mg, 100mg 08.01.05 Restricted Use NICE TA 663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Viekirax 12.5mg/75mg/50mg 05.03.03.02 Restricted Use NICE TA365 - Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C
Vinorelbine 20mg, 30mg, 80mg 08.01.04 Formulary NICE CG 81:Advanced Breast Cancer
Vortioxetine 5mg, 10mg, 20mg 04.03.04 Restricted Use NICE TA367: Vortioxetine for treating major depressive episodes
Zopiclone 3.75mg, 7.5mg 04.01.01 Restricted Use NICE TAG 77 :Zaleplon, zolpidem and zopiclone for the management of insomnia
Buckinghamshire Formulary